Comparison of Peptides and Traditional Anabolic Steroids

The Sledgehammer and the Scalpel

Peptides and anabolic-androgenic steroids (AAS) are often described as a scalpel and a sledgehammer. The sledgehammer half of that image holds up. Steroids act on the androgen receptor in muscle and almost every other tissue, and decades of research describe both their effects and their costs.

The scalpel half needs a caveat. Peptides such as ipamorelin and BPC-157 do act on narrower targets, but "precise" describes the mechanism, not the evidence. Most of what's known about performance peptides comes from animal studies and small human pilots, so their benefits and risks are less certain than the image suggests.

The two classes are also used for different goals. Steroids are taken to add muscle and strength. Peptides are mostly used to raise the body's own growth hormone or, in the case of BPC-157 and TB-500, to help with injuries.

How They Work: A Master Key vs. a Specific Key

Testosterone and synthetic relatives like nandrolone are fat-soluble. They cross the cell membrane and bind the androgen receptor inside the cell, and the pair then moves into the nucleus to switch on genes, including those that drive muscle protein synthesis. Androgen receptors also sit in skin, hair follicles, the prostate and the brain, so a high dose acts in all of them at once. A 2004 review in Sports Medicine by Hartgens and Kuipers notes that the body also converts some AAS into dihydrotestosterone, which acts on skin and prostate, or into estrogens. That's the master key.

Most peptides work from outside the cell. They're water-soluble and too large to cross the membrane, so they bind a surface receptor that sets off a signaling cascade inside. Ipamorelin, a GH secretagogue, binds the ghrelin receptor (GHS-R1a) on pituitary cells and prompts a pulse of the body's own growth hormone. In the 1998 study that introduced it, ipamorelin released growth hormone in rats and pigs. In pigs it didn't raise ACTH or cortisol, unlike GHRP-6 and GHRP-2. It doesn't act on the androgen receptor at all.

BPC-157 doesn't build muscle. Rodent studies suggest this 15-amino-acid peptide speeds tissue repair through growth factor signaling and new blood vessel growth (angiogenesis). A 2025 systematic review in HSS Journal found 36 eligible studies on its musculoskeletal effects. Thirty-five were preclinical and one was a small human case series, so the proposed mechanism has only been measured in animals.

The Inevitable Trade-Off: Side Effect Profiles

Steroid side effects are well documented. Hartgens and Kuipers describe suppression of the body's own testosterone production that can last for months after stopping, along with lower HDL cholesterol, higher blood pressure, acne and, in some users, more aggression. The DEA's fact sheet adds testicular shrinkage, breast tissue growth in men, and liver damage with oral steroids. A 2014 Endocrine Society scientific statement linked performance-enhancing drug use to a higher risk of death and to cardiovascular, psychiatric and endocrine disorders. Its authors warned that these risks are underappreciated, partly because users take far higher doses than any trial could ethically test.

Peptide side effects are less well mapped, which isn't the same as milder. Users of CJC-1295 and ipamorelin commonly report flushing, water retention and tingling hands, consistent with raised growth hormone. Few controlled trials exist to confirm those reports or catch rarer problems.

For BPC-157, the 2025 review found no clinical safety data. A 2025 pilot study gave intravenous BPC-157 (10 mg, then 20 mg the next day) to two adults and saw no side effects or changes in blood markers, but a study of two people can't reveal uncommon effects. For TB-500, FDA says it has not identified any human exposure data for the thymosin beta-4 fragment sold under that name.

The fair comparison is between large, well-documented risks for steroids and mostly unmeasured risks for peptides. Our article on long-term health risks of peptide use looks at what that gap means over years of use.

Let's Talk Raw Power: What Actually Builds More Muscle?

Steroids come out ahead here, and the human trial data is clear. In a 1996 trial in the New England Journal of Medicine, Bhasin and colleagues randomized 43 healthy men to weekly injections of 600 mg testosterone enanthate or placebo for 10 weeks, with or without weight training. The men given testosterone who also trained added about 6.1 kg of fat-free mass and about 22 kg to their bench press. Even without training, the testosterone group grew larger arm and thigh muscles than the placebo group. That dose was given under medical monitoring. The DEA says doses used outside medicine are often 10 to 100 times higher than therapeutic doses.

No published trial has measured muscle or strength gain from ipamorelin, CJC-1295 or BPC-157 in healthy adults who train. Users of growth hormone secretagogues mostly describe better sleep and recovery rather than large changes in muscle mass. Those reports are unverified, but they fit the mechanism: a pulse of the body's own growth hormone is a much weaker anabolic signal than direct androgen receptor activation.

Injury recovery is where peptides draw more interest. Lifters with tendon or joint problems often use BPC-157 and TB-500, sometimes together. Rodent data for BPC-157 on tendon, ligament and muscle healing is consistent, and we rate its evidence as emerging. TB-500 rates lower, as preliminary, because there's no human data on the fragment itself. Users describe mixed results, from faster improvement to no change after several weeks. Product quality may explain part of that gap, and no controlled human trial has measured tendon healing with either peptide.

The Black Market vs. The Gray Market

Anabolic steroids, including testosterone and trenbolone, are Schedule III controlled substances under federal law. Possessing or selling them without a prescription is a crime, so nonprescription supply runs through an illegal market where buyers can't check dose or sterility.

As of October 2026, none of the peptides discussed here is federally controlled. They're sold online as "research chemicals" not for human use, but that label doesn't make them legal to sell for people. In 2026 warning letters to peptide sellers, FDA said a "research use only" disclaimer doesn't protect a seller whose website shows the products are meant for humans. Its August 24, 2026 letter to one vendor cited the product descriptions and the sale of bacteriostatic water for mixing injections, and called the products unapproved new drugs.

In July 2026, a federal judge sentenced the owner of Paradigm Peptides to 70 months in prison after he pleaded guilty to selling unapproved drugs and illegal importation, CBS News reported. He admitted the company forged lab certificates, and government tests of six of its products sold as SARMs found actual testosterone in all six. That's the gray market's main risk for buyers: not knowing what's in the vial. Our guide to peptide sourcing and quality control covers what third-party tests can and can't show.

Also in July 2026, an FDA advisory committee recommended, over the objections of agency staff, broadening access to six peptides, BPC-157 among them. A recommendation isn't a rule. For tested athletes the question is settled either way: WADA's 2026 Prohibited List bans steroids (S1.1), BPC-157 (S0), TB-500 (S2.3), and ipamorelin, CJC-1295 and GHRP-2 (S2.2.4) at all times. Our articles on the legal landscape of peptides in sports and what "research use only" means legally have more detail.

Comparison table

What We Still Don't Know

No study has compared any peptide with a steroid head to head. Every comparison on this page sets human trial data for steroids against animal data and user reports for peptides.

There's no long-term human safety data for BPC-157 or TB-500, and the growth hormone secretagogues have only short studies. Real-world steroid risks are undercounted too. As the Endocrine Society statement notes, trials can't ethically use the doses and combinations that users take, so most of that evidence comes from observational studies.

The next development to watch is whether FDA acts on its advisory committee's July 2026 vote. A decision would change the legal position of BPC-157 and the other five peptides, but not the evidence behind them.